Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
Maryville University
School of Nursing
NURS 660 — Psychopharmacology and Advanced Mental Health
EXAMINATION 4
75 Questions | Complete Questions & Verified Answers
100% Correct | Graded A+
2026/2027 Academic Year
PMHNP-Aligned Format | NGN Standards
1
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
Section 1: Psychopharmacologic Mechanisms & Pharmacokinetics (Q1–Q8)
Q1. A psychiatric nurse practitioner is explaining receptor theory to a nursing student.
Which statement best describes the mechanism of a partial agonist at the receptor site?
A. It binds to the receptor and produces the same maximal effect as a full agonist
B. It binds to the receptor and produces a submaximal response even when all
receptors are occupied
C. It binds to the receptor and blocks the action of both agonists and antagonists
D. It binds to an allosteric site to modulate receptor activity indirectly
Rationale: A partial agonist binds to the same receptor site as a full agonist but produces only
a submaximal physiological response, even when 100% of receptors are occupied. This is
because partial agonists have lower intrinsic efficacy compared to full agonists. Examples in
psychopharmacology include aripiprazole (a partial D2 agonist) and buspirone (a partial 5-
HT1A agonist). Partial agonists can also act as functional antagonists in the presence of full
agonists by competing for receptor occupancy, making them clinically valuable for stabilizing
dopaminergic tone without producing excessive stimulation or complete blockade.
Q2. Which factor most significantly determines whether a psychotropic medication can
cross the blood-brain barrier (BBB)?
A. High molecular weight and water solubility
B. High lipid solubility and low molecular weight
C. High degree of ionization at physiological pH
D. Strong protein-binding capacity in the plasma
Rationale: The blood-brain barrier is a highly selective semipermeable membrane that
primarily allows passage of lipophilic (fat-soluble), low molecular weight, and un-ionized
molecules. Psychotropic medications must possess sufficient lipid solubility to passively diffuse
through the endothelial cells of the BBB. Highly ionized or large molecules generally cannot
cross efficiently unless specific active transport mechanisms exist. This pharmacokinetic
principle explains why lipophilic benzodiazepines (e.g., diazepam) cross the BBB rapidly
compared to more polar compounds, and why drugs with high protein binding may have
reduced free fractions available for CNS penetration.
Q3. A patient taking sertraline 200 mg daily is prescribed carbamazepine for comorbid
trigeminal neuralgia. What is the expected pharmacokinetic interaction?
A. Carbamazepine will increase sertraline levels by inhibiting CYP3A4
B. Sertraline will increase carbamazepine levels by inhibiting CYP3A4
C. Carbamazepine will decrease sertraline levels by inducing CYP3A4 and CYP2C19
D. No clinically significant interaction is expected between these two medications
2
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
Rationale: Carbamazepine is a potent inducer of multiple cytochrome P450 enzymes,
including CYP3A4, CYP2C19, and CYP1A2. Since sertraline is metabolized by multiple CYP450
enzymes including CYP3A4 and CYP2C19, coadministration with carbamazepine will accelerate
the metabolism of sertraline, leading to decreased plasma levels and potential loss of
antidepressant efficacy. The psychiatric nurse practitioner should anticipate the need for a
higher sertraline dose or consideration of an alternative mood stabilizer that does not induce
CYP450 enzymes, such as valproate or lamotrigine.
Q4. A patient of Asian descent is prescribed fluoxetine 20 mg daily for major depressive
disorder. Genetic testing reveals a CYP2D6 poor metabolizer phenotype. What is the
clinical implication?
A. The patient will metabolize fluoxetine too rapidly, requiring a higher dose
B. The patient will have increased fluoxetine levels and higher risk of toxicity
C. CYP2D6 status has no relevance for fluoxetine metabolism
D. The patient should be switched to a CYP2D6 substrate for better efficacy
Rationale: CYP2D6 is one of the primary enzymes responsible for metabolizing fluoxetine to its
active metabolite norfluoxetine. Patients with the CYP2D6 poor metabolizer (PM) phenotype
have significantly reduced enzymatic activity, leading to elevated plasma concentrations of
fluoxetine and norfluoxetine. This increases the risk of serotonin syndrome, QTc prolongation,
and other dose-dependent adverse effects. Approximately 5–10% of individuals of Asian descent
carry CYP2D6 PM alleles. Pharmacogenomic testing is recommended before prescribing
CYP2D6-metabolized psychotropics to guide dose selection and minimize toxicity risk. A dose
reduction or alternative SSRI may be warranted.
Q5. A patient with severe hepatic impairment (Child-Pugh Class C) requires treatment for
depression. Which pharmacokinetic consideration is most important?
A. Reduced first-pass metabolism leading to higher bioavailability of orally
administered drugs
B. Increased protein binding leading to lower free drug concentrations
C. Enhanced renal clearance of psychotropic metabolites
D. Accelerated phase I metabolism (oxidation) with preserved phase II metabolism (conjugation)
Rationale: In severe hepatic impairment, the liver's capacity for first-pass metabolism is
significantly reduced. The first-pass effect typically metabolizes a substantial portion of an
orally administered drug before it reaches systemic circulation. When hepatic function is
compromised, bioavailability increases substantially, meaning more of the active drug reaches
the systemic circulation. Additionally, decreased hepatic synthesis of albumin reduces protein-
binding capacity, increasing the free (active) fraction of highly protein-bound psychotropics.
Both phase I (oxidation, reduction) and phase II (conjugation) metabolic pathways are
3
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
impaired. Dose reductions of 50% or more are typically recommended for drugs undergoing
extensive hepatic metabolism in patients with severe liver disease.
Q6. Which of the following drug properties is associated with the greatest ability to cross
the blood-brain barrier? (Select All That Apply)
A. High lipophilicity (log P > 2)
B. Low molecular weight (< 400 Da)
C. High degree of ionization at physiological pH (7.4)
D. Low plasma protein binding
E. Structural similarity to endogenous CNS transport substrates
Rationale: Multiple drug properties influence BBB penetration. High lipophilicity (log P > 2)
facilitates passive diffusion across the lipid-rich endothelial cell membranes of the BBB. Low
molecular weight (< 400–500 Da) allows paracellular passage through tight junctions when
they are disrupted. Structural similarity to endogenous substrates (e.g., L-DOPA resembling
levodopa) allows utilization of specific carrier-mediated transport systems such as the large
neutral amino acid transporter (LAT1). Conversely, a high degree of ionization at physiological
pH significantly impairs BBB crossing, as charged molecules are poorly permeable across lipid
membranes. Low plasma protein binding is not a direct determinant of BBB crossing but rather
affects the free drug concentration available for distribution.
Q7. A patient is taking fluvoxamine, a potent CYP1A2 inhibitor. Which medication
interaction is most concerning due to elevated levels of the co-administered drug?
A. Olanzapine — increased risk of sedation and metabolic effects
B. Theophylline — increased risk of seizures and cardiac arrhythmias
C. Lithium — increased risk of lithium toxicity
D. Valproate — increased risk of hepatotoxicity
Rationale: Fluvoxamine is a potent inhibitor of CYP1A2, which is the primary enzyme
responsible for theophylline metabolism. Coadministration can increase theophylline plasma
concentrations by 2- to 3-fold, significantly raising the risk of serious theophylline toxicity
including seizures, tachyarrhythmias, and cardiovascular collapse. Theophylline has a narrow
therapeutic index (10–20 mcg/mL), making even modest CYP1A2 inhibition clinically
dangerous. While fluvoxamine also inhibits CYP2C19 and has some effect on CYP3A4 (affecting
olanzapine metabolism), the theophylline interaction represents the most immediately life-
threatening concern. Patients requiring both medications should have theophylline levels closely
monitored with dose reductions of 50% or more.
4
Maryville University
School of Nursing
NURS 660 — Psychopharmacology and Advanced Mental Health
EXAMINATION 4
75 Questions | Complete Questions & Verified Answers
100% Correct | Graded A+
2026/2027 Academic Year
PMHNP-Aligned Format | NGN Standards
1
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
Section 1: Psychopharmacologic Mechanisms & Pharmacokinetics (Q1–Q8)
Q1. A psychiatric nurse practitioner is explaining receptor theory to a nursing student.
Which statement best describes the mechanism of a partial agonist at the receptor site?
A. It binds to the receptor and produces the same maximal effect as a full agonist
B. It binds to the receptor and produces a submaximal response even when all
receptors are occupied
C. It binds to the receptor and blocks the action of both agonists and antagonists
D. It binds to an allosteric site to modulate receptor activity indirectly
Rationale: A partial agonist binds to the same receptor site as a full agonist but produces only
a submaximal physiological response, even when 100% of receptors are occupied. This is
because partial agonists have lower intrinsic efficacy compared to full agonists. Examples in
psychopharmacology include aripiprazole (a partial D2 agonist) and buspirone (a partial 5-
HT1A agonist). Partial agonists can also act as functional antagonists in the presence of full
agonists by competing for receptor occupancy, making them clinically valuable for stabilizing
dopaminergic tone without producing excessive stimulation or complete blockade.
Q2. Which factor most significantly determines whether a psychotropic medication can
cross the blood-brain barrier (BBB)?
A. High molecular weight and water solubility
B. High lipid solubility and low molecular weight
C. High degree of ionization at physiological pH
D. Strong protein-binding capacity in the plasma
Rationale: The blood-brain barrier is a highly selective semipermeable membrane that
primarily allows passage of lipophilic (fat-soluble), low molecular weight, and un-ionized
molecules. Psychotropic medications must possess sufficient lipid solubility to passively diffuse
through the endothelial cells of the BBB. Highly ionized or large molecules generally cannot
cross efficiently unless specific active transport mechanisms exist. This pharmacokinetic
principle explains why lipophilic benzodiazepines (e.g., diazepam) cross the BBB rapidly
compared to more polar compounds, and why drugs with high protein binding may have
reduced free fractions available for CNS penetration.
Q3. A patient taking sertraline 200 mg daily is prescribed carbamazepine for comorbid
trigeminal neuralgia. What is the expected pharmacokinetic interaction?
A. Carbamazepine will increase sertraline levels by inhibiting CYP3A4
B. Sertraline will increase carbamazepine levels by inhibiting CYP3A4
C. Carbamazepine will decrease sertraline levels by inducing CYP3A4 and CYP2C19
D. No clinically significant interaction is expected between these two medications
2
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
Rationale: Carbamazepine is a potent inducer of multiple cytochrome P450 enzymes,
including CYP3A4, CYP2C19, and CYP1A2. Since sertraline is metabolized by multiple CYP450
enzymes including CYP3A4 and CYP2C19, coadministration with carbamazepine will accelerate
the metabolism of sertraline, leading to decreased plasma levels and potential loss of
antidepressant efficacy. The psychiatric nurse practitioner should anticipate the need for a
higher sertraline dose or consideration of an alternative mood stabilizer that does not induce
CYP450 enzymes, such as valproate or lamotrigine.
Q4. A patient of Asian descent is prescribed fluoxetine 20 mg daily for major depressive
disorder. Genetic testing reveals a CYP2D6 poor metabolizer phenotype. What is the
clinical implication?
A. The patient will metabolize fluoxetine too rapidly, requiring a higher dose
B. The patient will have increased fluoxetine levels and higher risk of toxicity
C. CYP2D6 status has no relevance for fluoxetine metabolism
D. The patient should be switched to a CYP2D6 substrate for better efficacy
Rationale: CYP2D6 is one of the primary enzymes responsible for metabolizing fluoxetine to its
active metabolite norfluoxetine. Patients with the CYP2D6 poor metabolizer (PM) phenotype
have significantly reduced enzymatic activity, leading to elevated plasma concentrations of
fluoxetine and norfluoxetine. This increases the risk of serotonin syndrome, QTc prolongation,
and other dose-dependent adverse effects. Approximately 5–10% of individuals of Asian descent
carry CYP2D6 PM alleles. Pharmacogenomic testing is recommended before prescribing
CYP2D6-metabolized psychotropics to guide dose selection and minimize toxicity risk. A dose
reduction or alternative SSRI may be warranted.
Q5. A patient with severe hepatic impairment (Child-Pugh Class C) requires treatment for
depression. Which pharmacokinetic consideration is most important?
A. Reduced first-pass metabolism leading to higher bioavailability of orally
administered drugs
B. Increased protein binding leading to lower free drug concentrations
C. Enhanced renal clearance of psychotropic metabolites
D. Accelerated phase I metabolism (oxidation) with preserved phase II metabolism (conjugation)
Rationale: In severe hepatic impairment, the liver's capacity for first-pass metabolism is
significantly reduced. The first-pass effect typically metabolizes a substantial portion of an
orally administered drug before it reaches systemic circulation. When hepatic function is
compromised, bioavailability increases substantially, meaning more of the active drug reaches
the systemic circulation. Additionally, decreased hepatic synthesis of albumin reduces protein-
binding capacity, increasing the free (active) fraction of highly protein-bound psychotropics.
Both phase I (oxidation, reduction) and phase II (conjugation) metabolic pathways are
3
, Maryville NURS 660 — Psychopharmacology & Advanced Mental Health Exam 4
impaired. Dose reductions of 50% or more are typically recommended for drugs undergoing
extensive hepatic metabolism in patients with severe liver disease.
Q6. Which of the following drug properties is associated with the greatest ability to cross
the blood-brain barrier? (Select All That Apply)
A. High lipophilicity (log P > 2)
B. Low molecular weight (< 400 Da)
C. High degree of ionization at physiological pH (7.4)
D. Low plasma protein binding
E. Structural similarity to endogenous CNS transport substrates
Rationale: Multiple drug properties influence BBB penetration. High lipophilicity (log P > 2)
facilitates passive diffusion across the lipid-rich endothelial cell membranes of the BBB. Low
molecular weight (< 400–500 Da) allows paracellular passage through tight junctions when
they are disrupted. Structural similarity to endogenous substrates (e.g., L-DOPA resembling
levodopa) allows utilization of specific carrier-mediated transport systems such as the large
neutral amino acid transporter (LAT1). Conversely, a high degree of ionization at physiological
pH significantly impairs BBB crossing, as charged molecules are poorly permeable across lipid
membranes. Low plasma protein binding is not a direct determinant of BBB crossing but rather
affects the free drug concentration available for distribution.
Q7. A patient is taking fluvoxamine, a potent CYP1A2 inhibitor. Which medication
interaction is most concerning due to elevated levels of the co-administered drug?
A. Olanzapine — increased risk of sedation and metabolic effects
B. Theophylline — increased risk of seizures and cardiac arrhythmias
C. Lithium — increased risk of lithium toxicity
D. Valproate — increased risk of hepatotoxicity
Rationale: Fluvoxamine is a potent inhibitor of CYP1A2, which is the primary enzyme
responsible for theophylline metabolism. Coadministration can increase theophylline plasma
concentrations by 2- to 3-fold, significantly raising the risk of serious theophylline toxicity
including seizures, tachyarrhythmias, and cardiovascular collapse. Theophylline has a narrow
therapeutic index (10–20 mcg/mL), making even modest CYP1A2 inhibition clinically
dangerous. While fluvoxamine also inhibits CYP2C19 and has some effect on CYP3A4 (affecting
olanzapine metabolism), the theophylline interaction represents the most immediately life-
threatening concern. Patients requiring both medications should have theophylline levels closely
monitored with dose reductions of 50% or more.
4
